WO2012069423A1 - Method for the preparation of naproxen chloride - Google Patents

Method for the preparation of naproxen chloride Download PDF

Info

Publication number
WO2012069423A1
WO2012069423A1 PCT/EP2011/070577 EP2011070577W WO2012069423A1 WO 2012069423 A1 WO2012069423 A1 WO 2012069423A1 EP 2011070577 W EP2011070577 W EP 2011070577W WO 2012069423 A1 WO2012069423 A1 WO 2012069423A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
reaction
group
solvent
Prior art date
Application number
PCT/EP2011/070577
Other languages
French (fr)
Inventor
Yves Bessard
Original Assignee
Lonza Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza Ltd filed Critical Lonza Ltd
Publication of WO2012069423A1 publication Critical patent/WO2012069423A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/58Preparation of carboxylic acid halides
    • C07C51/60Preparation of carboxylic acid halides by conversion of carboxylic acids or their anhydrides or esters, lactones, salts into halides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/14Preparation of carboxylic acid esters from carboxylic acid halides

Definitions

  • the invention relates to a method for the preparation of 2-(6'-methoxy-2'-naphthyl)propionic acid chloride (naproxen chloride) using phosgene, and a method for the preparation of esters and amides derived from the thus prepared naproxen chloride.
  • Esters and amides derived from 2-(6'-methoxy-2'-naphthyl)propionic acid are known in the literature and are useful as drugs against inflammation, pain and pyrexia.
  • US Patent 4,048,330 and WO 2009/000723 A disclose methods for the preparation of 2-(6'- methoxy-2'-naphthyl)propionic acid chlorides using thionyl chloride, and derivates there from.
  • Subject of the invention is a method for the preparation of a compound of formula (I),
  • the compound (PhosA) is selected from the group consisting of phosgene, diphosgene,
  • reagent (A) is a compound of formula (PhosAl).
  • the method allows the preparation of both enantiomers individually and of a racemic mixture of the enantiomers of compound of formula (I). What is formed depends on which compound of formula (II) is used.
  • compound of formula (II) is a compound of formula (Il-down),
  • compound of formula (I) is a compound of formula (I-down).
  • compound of formula (I-down) is prepared by reaction (A) by using compound of formula (II-down).
  • the compound of formula (PhosAl) is a known compound and is made by a reaction of phosgene with dimethylformamide.
  • the compound (PhosA) is selected from the group consisting of monophosgene, diphosgene, triphosgene and compound of formula (PhosAl).
  • the compound (PhosA) and the compound of formula (II) are known compounds and can be prepared by known methods.
  • reaction (A) is carried out in the presence of a catalyst (A), the catalyst (A) being a compound of formula (III),
  • R4 and R5 are identical or different and independently from each other selected from the group consisting of hydrogen and C1.4 alkyl.
  • R4 and R5 are identical or different and are independently from each other
  • R4 and R5 are identical and are methyl or ethyl.
  • reaction time in reaction (A) is of from 5 min to 24 h, more preferably of from 10 min to 16 h, even more preferably of from 15 min to 8 h.
  • reaction (A) is carried out in a solvent (A), the solvent (A) being selected from the group consisting of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane, tetrahydrofurane (THF) and ethylacetate;
  • dichloromethane more preferably of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane and ethylacetate;
  • solvent (A) is dichloromethane.
  • reaction (A) is carried out at a pressure of from atmospheric pressure to 15 atm. More preferably the reaction (A) is carried out at atmospheric pressure.
  • the reaction (A) is carried out at a temperature of from -10 to 150 °C, more preferably of from -5 to 60 °C, even more preferably of from 0 to 40 °C.
  • the amount of solvent (A) is of from 0.1 to 10.0 fold, more preferably of from 1.0 to 6.0 fold, even more preferably of from 2.0 to 4.0 fold, of the weight of compound of formula (II).
  • mol-equivalents Preferably, of from 1.0 to 6.0 mol-equivalents, more preferably of from 1.0 to 4.0 mol- equivalents, even more preferably of from 1.3 to 2.0 mol-equivalents, of compound (PhosA) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
  • a catalyst (A) is used, then preferably, of from 0.01 to 1.50 mol-equivalents, more preferably of from 0.01 to 1.00 mol-equivalents, even more preferably of from 0.02 to 0.50 mol-equivalents, of catalyst (A) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
  • compound of formula (I) is isolated by standard procedures such as filtration and subsequent drying.
  • a precipitation is done by adding a precipitating solvent to the reaction mixture, preferably the precipitating solvent is selected from the group consisting of C5-8 alkane, Ci_4 alkyl C5-8 cycloalkane and mixtures thereof; more preferably of pentane, hexane, heptane, cyclopentane, cyclohexane, cycloheptane, C14 alkylcyclopentane, Ci-4 alkylcyclohexane, C alkylcycloheptane and mixtures thereof; with the C alkyl being preferably methyl or ethyl.
  • the precipitating solvent is selected from the group consisting of C5-8 alkane, Ci_4 alkyl C5-8 cycloalkane and mixtures thereof; more preferably of pentane, hexane, heptane, cyclopentane, cyclohexane, cycloheptane, C14 alkylcyclopentane, Ci-4 al
  • the precipitating solvent is n-hexane, methylcyclohexane or mixtures thereof. Further subject of the invention is a method for the preparation of a compound of formula (IV),
  • X is ORl or N(R2)R3 ;
  • Rl is selected from the group consisting of C 1-10 alkyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 , 2 or 3 substituents selected from the group consisting of halogene, CM alkoxy and nitro;
  • R2 and R3 are identical or different and are independently from each other selected from the group consisting of hydrogen, Ci-io alkyl, phenyl and benzyl, with R2 and R3 being independently from each other unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of halogene, CM alkoxy and nitro; characterized by two steps, the first step being the reaction (A) as defined above,
  • the second step being a reaction (B) of the compound of formula (I), which has been prepared in the first step, with a compound of formula (V),
  • Rl is selected from the group consisting of C1.4 alkyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C 1 -2 alkoxy.
  • R2 and R3 are identical or different and independently from each other selected from the group consisting of hydrogen, C alkyl, phenyl and benzyl, with R2 and R3 being independently from each other unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C 1-2 alkoxy
  • Rl is selected from the group consisting of methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 substituent selected from the group consisting of F, CI and methoxy.
  • R2 and R3 are identical or different and independently from each other selected from the group consisting of hydrogen, C 1-3 alkyl, phenyl and benzyl, the R2 and R3 being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C 1 -2 alkoxy.
  • Rl is selected from the group consisting of ethyl, 3-chloro-l-propyl, iso-propyl and benzyl.
  • R2 is hydrogen and R3 is benzyl; or R2 and R3 are iso-propyl.
  • compound of formula (IV) is a compound of formula (IV-down),
  • compound of formula (IV-down) is prepared by using compound of formula (II- down) in the first step of the reaction sequence, i .e. in the reaction (A).
  • reaction time in reaction (B) is of from 5 min to 30 h, more preferably of from 10 min to 24 h, even more preferably of from 30 min to 20 h.
  • reaction (B) is carried out in a solvent (B), the solvent (B) being selected from the group consisting of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane, tetrahydrofurane (THF) and ethylacetate;
  • dichloromethane more preferably of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane and ethylacetate;
  • solvent (B) is dichloromethane.
  • reaction (B) is carried out at atmospheric pressure.
  • reaction (B) is carried out at a temperature of from 0 to 200 °C, more preferably of from 5 to 100 °C, even more preferably of from 10 to 50 °C.
  • the amount of solvent (B) is of 0.1 to 10.0 fold, more preferably of from 1.0 to 6.0 fold, even more preferably of from 2.0 to 4.0 fold, of the weight of compound of formula (II).
  • mol-equivalents Preferably, of from 0.8 to 5.0 mol-equivalents, more preferably of from 0.9 to 3.0 mol- equivalents, even more preferably of from 1.0 to 2.0 mol-equivalents, of compound of formula (V) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
  • the compounds of formula (V) are known compounds and can be prepared by known methods.
  • the compound of formula (IV) is isolated by standard procedures such as washing the reaction mixture, evaporation of the reaction solvent and subsequent drying.
  • reaction (A) and reaction (B) are done consecutively without isolating the compound of formula (I), preferably solvent (A) and solvent (B) are identical.
  • reaction (A) and reaction (B) are done in one pot, and solvent (A) and solvent (B) are identical.
  • the use of the compound (PhosA) instead of thionyl chloride provides higher purities, i.e. less by products in the reaction (A).
  • a one pot synthesis of compound of formula (IV) starting from the compound of formula (II) thereby also enjoys this benefit, and this is important for the production of pharmacologically used compounds of formula (IV).
  • the yields can be improved by using phosgene and its derivatives instead of thionyl chloride.
  • conversion rate also called “conversion” or “conv” in the following, and the purity, both given in the below examples, were determined according to the following method:
  • Buffer 0.33% (v/v) AcOH in water, pH adjusted with 25 wt% aq. NaOH to 4.0
  • Injection volume was 1 ⁇ L.
  • a specific amount of sample in the range of 70 to 90 mg was dissolved in ca. 50 mL MeOH. To 1 mL of the prepared solution 19 mL of eluent were added. Injection volume was 10 ⁇ L.
  • Yields in examples 1 to 22 are crude yields without considering purity. Yields in examples 23 to 29 were calculated having taken into consideration the purity.
  • Example 8 of WO2009/000723 was repeated exactly as described. Yield obtained was 85 %.
  • Table 1 shows area %, determined according to HPLC method 1. "n.o. " means "not observed”.
  • Example 1 was repeated with the differences given in table 2.
  • Example 1 was repeated with the differences given in table 3, and the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20°C and before addition of n-Hexane.
  • Example 1 was repeated with the differences given in table 4.
  • the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before addition of n-Hexane.
  • the reaction temperature was changed as given in the table.
  • Example 1 was repeated with the differences given in table 5.
  • the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before addition of n-Hexane.
  • Table 5
  • Example 1 was repeated with the differences given in table 6.
  • Example 1 was repeated with the differences given in table 7.
  • Example 1 was repeated with the differences given in table 8.
  • Example 22 was repeated with the differences given in table 9 to produce different esters.
  • Example 22 was repeated with the differences given in table 10 and the further difference, that during the washes performed after cooling the reaction mixture to 0-5°C a suspension appeared.
  • the suspension was filtered off.
  • the organic phase of the resulting mother liquor was evaporated and the solid obtained after evaporation was combined with the solid obtained after filtration.
  • the combined solids consisted of compound of formula (5). Analysis and yield obtained are detailed in table 10.
  • Example 27 was repeated with the differences given in table 1 1 and the further difference, that after cooling to 0 to 5°C, the mixture was washed 6 times (100 mL each) with 10% aq. sodium carbonate instead of 3 times, and then 2 times (100 mL) with water each instead of 1 time.
  • Table 11

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a method for the preparation of 2-(6'-methoxy-2'-naphthyl)propionic acid chloride(naproxen chloride) using phosgene, and a method for the preparation of esters and amides derived from the thus prepared naproxen chloride.

Description

Method for the preparation of naproxen chloride
The invention relates to a method for the preparation of 2-(6'-methoxy-2'-naphthyl)propionic acid chloride (naproxen chloride) using phosgene, and a method for the preparation of esters and amides derived from the thus prepared naproxen chloride.
Esters and amides derived from 2-(6'-methoxy-2'-naphthyl)propionic acid are known in the literature and are useful as drugs against inflammation, pain and pyrexia. US Patent 4,048,330 and WO 2009/000723 A disclose methods for the preparation of 2-(6'- methoxy-2'-naphthyl)propionic acid chlorides using thionyl chloride, and derivates there from.
Since the 2-(6'-methoxy-2'-naphthyl)propionic acid derivatives are used as drugs, a high degree of purity is desired and mandatory. The analysis of products prepared by the known methods using thionyl chloride shows impurities. There was a need for an improved process which provides products with higher purity. Surprisingly, by the disclosed process the problem can be solved. Halogen in the following means F, CI, Br or I; alkyl comprises linear or branched alkyl; if not otherwise stated.
Subject of the invention is a method for the preparation of a compound of formula (I),
Figure imgf000002_0001
characterized by a reaction (A) of a compound of formula (II)
Figure imgf000003_0001
with a compound (PhosA),
the compound (PhosA) is selected from the group consisting of phosgene, diphosgene,
triphosgene and reagent (A),
reagent (A) is a compound of formula (PhosAl).
(PhosAl)
Figure imgf000003_0002
Compound of formula (II) is called naproxen, compound of formula (I) is called naproxen chloride.
The method allows the preparation of both enantiomers individually and of a racemic mixture of the enantiomers of compound of formula (I). What is formed depends on which compound of formula (II) is used.
Preferably, compound of formula (II) is a compound of formula (Il-down),
Figure imgf000003_0003
Preferably, compound of formula (I) is a compound of formula (I-down).
Figure imgf000004_0001
Preferably, compound of formula (I-down) is prepared by reaction (A) by using compound of formula (II-down).
The compound of formula (PhosAl) is a known compound and is made by a reaction of phosgene with dimethylformamide.
Preferably, the compound (PhosA) is selected from the group consisting of monophosgene, diphosgene, triphosgene and compound of formula (PhosAl).
The compound (PhosA) and the compound of formula (II) are known compounds and can be prepared by known methods.
Preferably the reaction (A) is carried out in the presence of a catalyst (A), the catalyst (A) being a compound of formula (III),
O
H - R4 (in)
R5
wherein
R4 and R5 are identical or different and independently from each other selected from the group consisting of hydrogen and C1.4 alkyl.
More preferably, R4 and R5 are identical or different and are independently from each other
C alkyl.
Even more preferably, R4 and R5 are identical and are methyl or ethyl.
Preferably the reaction time in reaction (A) is of from 5 min to 24 h, more preferably of from 10 min to 16 h, even more preferably of from 15 min to 8 h. Preferably the reaction (A) is carried out in a solvent (A), the solvent (A) being selected from the group consisting of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane, tetrahydrofurane (THF) and ethylacetate;
more preferably of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane and ethylacetate;
even more preferably of dichloromethane, chlorobenzene and ethylacetate;
especially, solvent (A) is dichloromethane.
Preferably the reaction (A) is carried out at a pressure of from atmospheric pressure to 15 atm. More preferably the reaction (A) is carried out at atmospheric pressure.
Preferably the reaction (A) is carried out at a temperature of from -10 to 150 °C, more preferably of from -5 to 60 °C, even more preferably of from 0 to 40 °C. Preferably, the amount of solvent (A) is of from 0.1 to 10.0 fold, more preferably of from 1.0 to 6.0 fold, even more preferably of from 2.0 to 4.0 fold, of the weight of compound of formula (II).
Preferably, of from 1.0 to 6.0 mol-equivalents, more preferably of from 1.0 to 4.0 mol- equivalents, even more preferably of from 1.3 to 2.0 mol-equivalents, of compound (PhosA) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
If a catalyst (A) is used, then preferably, of from 0.01 to 1.50 mol-equivalents, more preferably of from 0.01 to 1.00 mol-equivalents, even more preferably of from 0.02 to 0.50 mol-equivalents, of catalyst (A) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
Preferably compound of formula (I) is isolated by standard procedures such as filtration and subsequent drying.
Preferably before a filtration, a precipitation is done by adding a precipitating solvent to the reaction mixture, preferably the precipitating solvent is selected from the group consisting of C5-8 alkane, Ci_4 alkyl C5-8 cycloalkane and mixtures thereof; more preferably of pentane, hexane, heptane, cyclopentane, cyclohexane, cycloheptane, C14 alkylcyclopentane, Ci-4 alkylcyclohexane, C alkylcycloheptane and mixtures thereof; with the C alkyl being preferably methyl or ethyl.
Especially the precipitating solvent is n-hexane, methylcyclohexane or mixtures thereof. Further subject of the invention is a method for the preparation of a compound of formula (IV),
Figure imgf000006_0001
wherein
X is ORl or N(R2)R3 ;
Rl is selected from the group consisting of C1-10 alkyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 , 2 or 3 substituents selected from the group consisting of halogene, CM alkoxy and nitro;
R2 and R3 are identical or different and are independently from each other selected from the group consisting of hydrogen, Ci-io alkyl, phenyl and benzyl, with R2 and R3 being independently from each other unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of halogene, CM alkoxy and nitro; characterized by two steps, the first step being the reaction (A) as defined above,
the second step being a reaction (B) of the compound of formula (I), which has been prepared in the first step, with a compound of formula (V),
X
H
(V) wherein the X in formula (V) has the same definition as and is identical with the X in formula (IV). Preferably, Rl is selected from the group consisting of C1.4 alkyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C1 -2 alkoxy.
Preferably, R2 and R3 are identical or different and independently from each other selected from the group consisting of hydrogen, C alkyl, phenyl and benzyl, with R2 and R3 being independently from each other unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C1-2 alkoxy
More preferably, Rl is selected from the group consisting of methyl, ethyl, n-propyl, iso- propyl, n-butyl, iso-butyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1 substituent selected from the group consisting of F, CI and methoxy.
More preferably, R2 and R3 are identical or different and independently from each other selected from the group consisting of hydrogen, C1-3 alkyl, phenyl and benzyl, the R2 and R3 being unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, CI, Br and C1 -2 alkoxy.
Even more preferably, Rl is selected from the group consisting of ethyl, 3-chloro-l-propyl, iso-propyl and benzyl.
Even more preferably, R2 is hydrogen and R3 is benzyl; or R2 and R3 are iso-propyl.
Preferably, compound of formula (IV) is a compound of formula (IV-down),
Figure imgf000007_0001
Preferably, compound of formula (IV-down) is prepared by using compound of formula (II- down) in the first step of the reaction sequence, i .e. in the reaction (A).
Preferably the reaction time in reaction (B) is of from 5 min to 30 h, more preferably of from 10 min to 24 h, even more preferably of from 30 min to 20 h. Preferably the reaction (B) is carried out in a solvent (B), the solvent (B) being selected from the group consisting of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane, tetrahydrofurane (THF) and ethylacetate;
more preferably of dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane and ethylacetate;
even more preferably of dichloromethane, chlorobenzene and ethylacetate;
especially, solvent (B) is dichloromethane.
Preferably the reaction (B) is carried out at atmospheric pressure.
Preferably the reaction (B) is carried out at a temperature of from 0 to 200 °C, more preferably of from 5 to 100 °C, even more preferably of from 10 to 50 °C.
Preferably, the amount of solvent (B) is of 0.1 to 10.0 fold, more preferably of from 1.0 to 6.0 fold, even more preferably of from 2.0 to 4.0 fold, of the weight of compound of formula (II).
Preferably, of from 0.8 to 5.0 mol-equivalents, more preferably of from 0.9 to 3.0 mol- equivalents, even more preferably of from 1.0 to 2.0 mol-equivalents, of compound of formula (V) are used, with the mol-equivalents being based on the moles used of compound of formula (II).
The compounds of formula (V) are known compounds and can be prepared by known methods. Preferably, the compound of formula (IV) is isolated by standard procedures such as washing the reaction mixture, evaporation of the reaction solvent and subsequent drying.
Preferably, the washing of the reaction mixture is done with aqueous sodium carbonate or with water or with both. Preferably reaction (A) and reaction (B) are done consecutively without isolating the compound of formula (I), preferably solvent (A) and solvent (B) are identical.
More preferably reaction (A) and reaction (B) are done in one pot, and solvent (A) and solvent (B) are identical. Surprisingly, the use of the compound (PhosA) instead of thionyl chloride provides higher purities, i.e. less by products in the reaction (A). A one pot synthesis of compound of formula (IV) starting from the compound of formula (II) thereby also enjoys this benefit, and this is important for the production of pharmacologically used compounds of formula (IV).
Also the yields can be improved by using phosgene and its derivatives instead of thionyl chloride.
Furthermore, when an entiomerically pure compound of formula (II) is used as starting material, the use of phosgene allows for the production of enantiomerically pure compounds of formula (I) and (IV), i.e. no racemization occurs.
Examples
List of Abbreviations and Raw materials
DCM dichloromethane
DMF dimethylform amide
eq. molar equivalent to the respective reagent of the reference example
NMR Nuclear Magnetic Resonance
HPLC High Pressure Liquid Chromatography
IPC In Process Control
RRT relative retention time: the retention time was expressed relative to the
respective reaction product, if not otherwise stated
THF tetrahydrofurane
Compound of formula (II-down) was used in commercial quality
Method Description
HPLC Method 1): Determination of conversion rate and purity
The conversion rate, also called "conversion" or "conv" in the following, and the purity, both given in the below examples, were determined according to the following method:
Waters Symmetry CI 8, 250.0 x 4.6mm, 5pm, temperature 40°C
Flow: 0.8 mL/min
Mobile phase A: acetonitrile
Mobile phase B: buffer
Buffer: 0.33% (v/v) AcOH in water, pH adjusted with 25 wt% aq. NaOH to 4.0
Run time: 30 min
Gradient composition: 67% mobile phase A and 33% mobile phase B
Detection at 232 nm
Sample preparation
A specific amount of sample of 50 mg was dissolved in 50 mL acetonitrile.
Injection volume was 1 μL.
HPLC Method 2): Determination of enantiomeric purity
The enantiomeric purity, given in the below examples, was determined according to the following method:
Regis (S,S)-WHELK-0-l (5pm), Ι ΟθΑ, 250 x 4.6mm I.D., temperature 25°C Flow: 2.0 mL/min
Eluent: 850 mL of methanol and 150 mL of water.
Run time: 20 min
Gradient composition: 100% eluent
Detection at 232 nm
Sample preparation
A specific amount of sample in the range of 70 to 90 mg was dissolved in ca. 50 mL MeOH. To 1 mL of the prepared solution 19 mL of eluent were added. Injection volume was 10 μL.
Yields in examples 1 to 22 are crude yields without considering purity. Yields in examples 23 to 29 were calculated having taken into consideration the purity.
LOD-method (Loss on Drying-method)
A small portion (1 to 5 g) of the wet cake, which was obtained after filtration, was taken and dried under nitrogen over night. The thereby determined dry content was used to calculate the dry content of the wet cake.
Example 1
To a suspension of compound of formula (II-down) (30.5 g, 132.4 mmol), DCM as solvent (78 ml) and DMF as catalyst (0.51 g, 7.0 mmol) at 20 to 25°C, phosgene as chlorination agent (25.6 g / 258.8 mmol) was added in 20 min. The mixture was stirred at 20 to 25°C for 1.5 h (conversion 99%). The DCM was distilled off at an inner temperature of 35 to 40°C until having a final volume of ca. 50 mL. The resulting suspension was cooled to 5 to 10°C in ca. 1 h. n-Hexane (252 ml) was added in the process of the cooling. After stirring for another 2 h the solid was filtered off under Nitrogen. The filtrate was washed with n-Hexane (2 times with 32mL each). 29.1 g of compound of formula (I-down) (118 mmol) were obtained based on LOD-method.
Yield: 89% yield
Purity: 99.2%.
Enantiomeric purity: 0.5 area% (R)-enantiomer (HPLC, method 2)
Comparative example 1
Example 8 of WO2009/000723 was repeated exactly as described. Yield obtained was 85 %.
Comparison of the impurity profile is given in table 1. Clearly, the method of instant invention provides higher purity. Table 1 shows area %, determined according to HPLC method 1. "n.o. " means "not observed".
Figure imgf000012_0002
Example 2
Example 1 was repeated with the differences given in table 2.
Figure imgf000012_0001
Examples 3, 4 and 5
Example 1 was repeated with the differences given in table 3, and the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20°C and before addition of n-Hexane.
Figure imgf000013_0001
Examples 6, 7, 8, 9, 10 and 11
Example 1 was repeated with the differences given in table 4. In examples 7 and 8, the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before addition of n-Hexane. In example 7, also the reaction temperature was changed as given in the table.
Figure imgf000013_0002
Examples 12, 13 and 14
Example 1 was repeated with the differences given in table 5. In examples 13 and 14, the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before addition of n-Hexane. Table 5
Ex Phosgene eq. DMF Conversion Reaction yield Purity R- eq. time Enantiomer
HPLC
12 1.50 0.10 96% 2 h 92% 99.0% 0.5%
13 1.25 0.10 69% 5 h - - -
14 3.00 1.00 >99% 1 h - - -
Examples 15 and 16
Example 1 was repeated with the differences given in table 6.
In example 16, the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before addition of n-Hexane.
Figure imgf000014_0001
Examples 17, 18, 19 and 20
Example 1 was repeated with the differences given in table 7.
In examples 17, 18, 19 and 20, the compound of formula (I-down) was not isolated, instead the reaction sequence ended after cooling to 20 to 25°C and before n-Hexane was added.
Figure imgf000014_0002
Example 21
Example 1 was repeated with the differences given in table 8.
In example 21, the compound of formula (I-down) was isolated using methyl cyclohexane instead of n-Hexane. Table 8
Ex DMF eq. Reaction time Conversion yield Purity
21 0.10 2 h 97% 80% 99.2%
Example 22
To a suspension of compound of formula (II-down) (30.5 g, 132.4 mmol), DCM as solvent (78 ml) and DMF as catalyst (0.51 g, 7.0 mmol) at 20°C, phosgene as chlonnation agent (25.6 g / 258.8 mmol) was added in 20 min. The mixture was stirred at 20°C for 3 h (conversion (1) 98%). The DCM was distilled off at an inner temperature of 35 to 40°C under pressure until having a final volume of ca. 50 mL. DCM (ca. 30 mL) was then added until having replaced the amount, which had been distilled off. The solution was cooled to 20°C and n-butanol (13.5 g, 193.4 mmol) was added. After a reaction time of 19 h (conversion (2) 99%) the mixture was cooled to 0 to 5°C and washed with 10% aq. sodium carbonate (3 times with 100 mL each) and with water (100 mL). The organic phase was distilled off until dryness and 35.5 g of compound of formula (1) (125 mmol) were obtained.
Yield 96%
Purity 98.8%
1H MR (500 MHz, CDC13): δ = 7.68 (m, 3H), 7.40 (dd, J = 8.5 and 1.8 Hz, 1H), 7.13 (m, 1H), 7.10 (d, J = 2.4 Hz, 1H), 4.07 (m, 2H), 3.90 (s, 3H), 3.84 (q, J = 7.2 Hz, 1H), 1.57 (d, J = 7.2 Hz, 3H), 1.53 (m, 2H), 1.28 (m, 2H), 0.85 (t, J = 7.5 Hz, 3H).
Figure imgf000015_0001
Examples 23, 24 and 25
Example 22 was repeated with the differences given in table 9 to produce different esters.
Figure imgf000016_0001
NMR data of compound of formula (2) obtained in example
Figure imgf000016_0002
1H MR (500 MHz, CDC13): δ = 7.69 (m, 2H), 7.64 (d, J = 1.8 Hz, 1H), 7.38 (dd, J = 8 and 1.8 Hz, 1H), 7.13 (m, 1H), 7.10 (d, J = 2.5 Hz, 1H), 4.22 (m, 2H), 3.89 (s, 3H), 3.84 = 7.1 Hz, 1H), 3.43 (m, 2H), 2.00 (m, 2H), 1.57 (d, J = 7.1 Hz, 3H).
NMR data of compound of formula (3) obtained in example
Figure imgf000016_0003
1H NMR (500 MHz, CDC13): δ = 7.69 (m, 2H), 7.66 (d, J = 1.8 Hz, 1H), 7.40 (dd, J = 8.6 and 1.8 Hz, 1H), 7.13 (m, 1H), 7.1 1 (d, J = 2.5 Hz, 1H), 5.00 (spt, J = 6.4 Hz, 1H), 3.91 (s, 3H), 3.80 (q, J = 7.0 Hz, 1H), 1.55 (d, J = 7.0 Hz, 3H), 1.22 (d, J = 6.4 Hz, 3H), 1.12 (d, J = 6.4 Hz, 3H). NMR data of compound of formula (4) obtained in example 25:
Figure imgf000017_0001
1H MR (500 MHz, CDC13): δ = 7.65 (m, 3H), 7.39 (dd, J = 8.5 and 2.0 Hz, 1H), 7.19 - 7.29 (m, 5H), 7.12 (dd, J = 8.8 and 2.5 Hz, 1H), 7.09 (d, J = 2.5 Hz, 1H), 5.10 (AB system, J = 12.4 Hz, 2H), 3.89 (q, J = 7.1 Hz, 1H), 3.88 (s, 3H), 1.58 (d, J = 7.1 Hz, 3H).
Example 26
Example 22 was repeated with the differences given in table 10 and the further difference, that during the washes performed after cooling the reaction mixture to 0-5°C a suspension appeared. The suspension was filtered off. The organic phase of the resulting mother liquor was evaporated and the solid obtained after evaporation was combined with the solid obtained after filtration. The combined solids consisted of compound of formula (5). Analysis and yield obtained are detailed in table 10.
Figure imgf000017_0003
NMR data of compound of formula (5) obtained in example
(5)
Figure imgf000017_0002
1H MR (500 MHz, CDC13): δ = 7.69 (m, 2H), 7.66 (d, J = 1.8 Hz, 1H), 7.40 (dd, J = 8.4 and 1.8 Hz, lH), 7.13 (m, 1H), 7.1 1 (d, J = 2.5 Hz, 1H), 4.13 (m, 2H), 3.90 (s, 3H), 3.83 (q, J = 7.1 Hz, 1H), 1.57 (d, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). Example 27
To a suspension of compound of formula (II-down) (30.5 g, 132.4 mmol), DCM as solvent (78 ml) and DMF as catalyst (0.51 g, 7.0 mmol) at 20°C, phosgene as chlorination agent (25.6 g, 258.8 mmol) was added in 20 min. The mixture was stirred at 20 to 25°C for 2.5 h (reaction time 1) (conversion (1) 98%). The DCM was distilled off at an inner temperature of 35 to 40°C under pressure until having a final volume of ca. 50 mL. DCM (ca. 30 mL) was then added until having replaced the amount distilled. The solution was cooled to 20°C and benzyl amine (28.8 g, 270 mmol) was added. After stirring for 18 h (reaction time 2) (conversion (2) 98%), the mixture was cooled to 0 to 5°C and washed with 10% aq. sodium carbonate (3 times with 100 mL each) and with water (100 mL). The organic phase was distilled off until dryness and 32.6 g of compound of formula (6) (101 mmol) were obtained.
Yield 76%
Purity 96%
1H MR (500 MHz, CDC13): δ = 7.70 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 9. 1 Hz, 1H), 7.65 (d, J = 1.8 Hz, 1H), 7.38 (dd, J = 8.5 and 1.8 Hz, 1H), 7.23 (m, 3H), 7.13 (m, 4H), 5. 13 (br. s., 1H), 4.37 (m, 2H), 3.90 (s, 3H), 3.72 (q, J = 7.1 Hz, 1H), 1.62 (d, J = 7.1 Hz, 3H).
Figure imgf000018_0001
Example 28
Example 27 was repeated with the differences given in table 1 1 and the further difference, that after cooling to 0 to 5°C, the mixture was washed 6 times (100 mL each) with 10% aq. sodium carbonate instead of 3 times, and then 2 times (100 mL) with water each instead of 1 time. Table 11
Ex Amine Reaction Conv (1) Reaction Conv (2) yield Purity time 1 time 2
28 Diisopropyl- 1 h 99% 44 h 94% 75% 96% amine
NMR data of compound of formula (7) obtained in example
Figure imgf000019_0001
IH NMR (500 MHz, CDC13): δ = 7.68 (m, 2H), 7.59 (d, J = 1.8 Hz, IH), 7.35 (dd, J = 8.5 and 1.8 Hz, IH), 7.12 (m, IH), 7.10 (d, J = 2.5 Hz, IH), 4.09 (spt, J = 6.6 Hz, IH), 3.93 (q, J = 6.7 Hz, IH), 3.89 (s, 3H), 3.30 (m, IH), 1.46 (m, 6H), 1.40 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H), 0.52 (d, J = 6.6 Hz, 3H).

Claims

Claims
1. A method for the preparation of a compound of formula (I),
Figure imgf000020_0001
characterized by a reaction (A) of a compound of formula (II)
Figure imgf000020_0002
with a compound (PhosA),
the compound (PhosA) is selected from the group consisting of phosgene, diphosgene,
triphosgene and reagent (A),
reagent (A) is a compound of formula (PhosAl).
H3C cf
H3C CH (PhosAl)
CI
2. Method according to claim 1, wherein the compound of formula (II) is a compound of formula (II-down).
Figure imgf000020_0003
3. Method according to claim 1 or 2, wherein compound (PhosA) is selected from the group consisting of monophosgene, diphosgene, triphosgene and compound of formula (PhosAl).
(PhosAl)
Figure imgf000021_0001
4. Method according to one or more of claims 1 to 3, wherein the reaction (A) is carried out in the presence of a catalyst (A), the catalyst (A) being a compound of formula (III),
Figure imgf000021_0002
R5
wherein
R4 and R5 are identical or different and independently from each other selected from the group consisting of hydrogen and Cm alkyl.
5. Method according to one or more of claims 1 to 3, wherein the reaction (A) is out in a solvent (A), the solvent (A) being selected from the group consisting of
dichloromethane, chlorobenzene, toluene, acetonitrile, dioxane, tetrahydrofurane and ethyl acetate.
Method for the preparation of a compound of formula (IV),
Figure imgf000021_0003
wherein
X is ORl or N(R2)R3; Rl is selected from the group consisting of Ci_io alkyl, phenyl and benzyl, with Rl being unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of halogene, C1.4 alkoxy and nitro;
R2 and R3 are identical or different and are independently from each other selected from the group consisting of hydrogen, CMO alkyl, phenyl and benzyl, with R2 and R3 being independently from each other unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of halogene, C1-4 alkoxy and nitro; characterized by two steps, the first step being the reaction (A) being as defined in one or more of claims 1 to 5,
the second step being a reaction (B) of the compound of formula (I), which has been prepared in the first step, with a compound of formula (V),
^ X
H
(V) wherein the X in formula (V) has the same definition as and is identical with the X in formula (IV).
7. Method according to claim 6, wherein reaction (A) and reaction (B) are done consecutively without isolating the compound of formula (I).
PCT/EP2011/070577 2010-11-26 2011-11-21 Method for the preparation of naproxen chloride WO2012069423A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP10015032 2010-11-26
EP10015032.5 2010-11-26
US201161503653P 2011-07-01 2011-07-01
US61/503,653 2011-07-01
EP11006377 2011-08-03
EP11006377.3 2011-08-03

Publications (1)

Publication Number Publication Date
WO2012069423A1 true WO2012069423A1 (en) 2012-05-31

Family

ID=44999787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/070577 WO2012069423A1 (en) 2010-11-26 2011-11-21 Method for the preparation of naproxen chloride

Country Status (2)

Country Link
TW (1) TW201305103A (en)
WO (1) WO2012069423A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048330A (en) 1967-01-13 1977-09-13 Syntex Corporation Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia
WO2009000723A1 (en) 2007-06-28 2008-12-31 Nicox S.A. Process for preparing 1,4-butandiol mononitrate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048330A (en) 1967-01-13 1977-09-13 Syntex Corporation Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia
WO2009000723A1 (en) 2007-06-28 2008-12-31 Nicox S.A. Process for preparing 1,4-butandiol mononitrate

Also Published As

Publication number Publication date
TW201305103A (en) 2013-02-01

Similar Documents

Publication Publication Date Title
EP2480523B1 (en) Process for manufacture of n-acylbphenyl alanine
JP2009531313A5 (en)
KR20190025990A (en) Method for producing 4-alkoxy-3- (acyl or alkyl) oxypicolinamide
US20200190056A1 (en) Processes for the preparation of niraparib and intermediates thereof
CA2889650C (en) Process and intermediates for preparing lacosamide
EP2935255A1 (en) A process for preparation of rivaroxaban
KR100481570B1 (en) Intermediates for the preparation of 2-imidazoline-5-ones
CN107868033B (en) Preparation method of phenylalanine compound
WO2009047797A2 (en) Process for the preparation of perhydroisoindole derivative
WO2012069423A1 (en) Method for the preparation of naproxen chloride
CN109988070B (en) Intermediate of trans-1-hydroxy-1- (trifluoromethyl) -3-aminocyclobutane hydrochloride, preparation method and application
WO2011060624A1 (en) Process for preparing 2-methyl-4-amino-5-cyanopyrimidine
JP4406482B2 (en) Process for producing optically active 2-aminocyclohexanol derivative
EP3260442B1 (en) Process for preparation of optically pure n-substituted-3-methoxypropionic acid derivatives
CA2792473A1 (en) A process for the preparation of highly pure ambrisentan
CN106892879B (en) Synthetic method of anti-gout drug febuxostat
KR100900573B1 (en) Preparation method of s-atenolol
CN114805220A (en) Preparation method of quinazolinone compound
CN111333552A (en) β -benzo amino acid compound synthesis method
EP3600298A1 (en) Synthetic processes and synthetic intermediates
EP2785681A1 (en) Process for the preparation of agomelatine
CN114907283A (en) Preparation method of 2- (3, 5-dichlorophenyl) -benzoxazole-6-carboxylic acid
CN115246781A (en) Preparation method of safinamide
WO2013054273A9 (en) Process for the preparation of agomelatine
CN110551114A (en) Preparation method of raltitrexed

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11785027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11785027

Country of ref document: EP

Kind code of ref document: A1